The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Simvastatin (Primary)
- Indications Lymphangioleiomyomatosis; Tuberous sclerosis
- Focus Adverse reactions
- Acronyms SOS
Most Recent Events
- 12 Aug 2020 Time frame for primary outcome changed from 3 months to 5 months
- 12 Aug 2020 Status changed from active, no longer recruiting to completed.
- 01 Feb 2019 Planned End Date changed from 1 May 2019 to 1 Dec 2019.